Susan Davis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3810539/publications.pdf

Version: 2024-02-01

409 papers 23,974 citations

7096 78 h-index 9861 141 g-index

432 all docs 432 docs citations

times ranked

432

16108 citing authors

#	Article	IF	CITATIONS
1	Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet, The, 2013, 381, 805-816.	13.7	1,664
2	Androgen Levels in Adult Females: Changes with Age, Menopause, and Oophorectomy. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 3847-3853.	3.6	841
3	Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3975-4011.	3.6	589
4	Postmenopausal Hormone Therapy: An Endocrine Society Scientific Statement. Journal of Clinical Endocrinology and Metabolism, 2010, 95, s1-s66.	3.6	512
5	Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas, 1995, 21, 227-236.	2.4	488
6	Circulating Androgen Levels and Self-reported Sexual Function in Women. JAMA - Journal of the American Medical Association, 2005, 294, 91.	7.4	451
7	Understanding weight gain at menopause. Climacteric, 2012, 15, 419-429.	2.4	430
8	Testosterone Patch Increases Sexual Activity and Desire in Surgically Menopausal Women with Hypoactive Sexual Desire Disorder. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 5226-5233.	3.6	428
9	Testosterone for Low Libido in Postmenopausal Women Not Taking Estrogen. New England Journal of Medicine, 2008, 359, 2005-2017.	27.0	427
10	Female androgen insufficiency: the princeton consensus statement on definition, classification, and assessment. Fertility and Sterility, 2002, 77, 660-665.	1.0	408
11	Minireview: Aromatase and the Regulation of Estrogen Biosynthesis—Some New Perspectives. Endocrinology, 2001, 142, 4589-4594.	2.8	405
12	Dysmetabolic Syndrome in a Man with a Novel Mutation of the Aromatase Gene: Effects of Testosterone, Alendronate, and Estradiol Treatment. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 61-70.	3.6	315
13	Phytoestrogens. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 297-303.	3.6	294
14	Menopause. Nature Reviews Disease Primers, 2015, 1, 15004.	30.5	288
15	Androgen Therapy in Women: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 3697-3710.	3.6	286
16	Phytoestrogens ¹ . Journal of Clinical Endocrinology and Metabolism, 1998, 83, 297-303.	3.6	273
17	The Relationship Between Self-Reported Sexual Satisfaction and General Well-Being in Women. Journal of Sexual Medicine, 2009, 6, 2690-2697.	0.6	267
18	Androgen Therapy in Women: A Reappraisal: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3489-3510.	3.6	261

#	Article	IF	CITATIONS
19	The North American Menopause Society Recommendations for Clinical Care of Midlife Women. Menopause, 2014, 21, 1038-1062.	2.0	258
20	Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric, 2013, 16, 316-337.	2.4	255
21	Dietary Soy Has Both Beneficial and Potentially Adverse Cardiovascular Effects: A Placebo-Controlled Study in Men and Postmenopausal Women1. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3053-3060.	3.6	252
22	Transdermal testosterone therapy improves well-being, mood, and sexual function in premenopausal women. Menopause, 2003, 10, 390-398.	2.0	246
23	Association of cartilage defects with loss of knee cartilage in healthy, middle-age adults: A prospective study. Arthritis and Rheumatism, 2005, 52, 2033-2039.	6.7	237
24	Dietary Soy Has Both Beneficial and Potentially Adverse Cardiovascular Effects: A Placebo-Controlled Study in Men and Postmenopausal Women. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3053-3060.	3.6	231
25	Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women. Menopause, 2006, 13, 387-396.	2.0	230
26	Effects of intranasal $17\hat{l}^2$ -estradiol administration on serum bioactive interleukin-6 and C-reactive protein levels in healthy postmenopausal women. Menopause, 2006, 13, 840-845.	2.0	229
27	Summary of the Recommendations on Sexual Dysfunctions in Women. Journal of Sexual Medicine, 2004, 1, 24-34.	0.6	214
28	The Role of Local Estrogen Biosynthesis in Males and Females. Trends in Endocrinology and Metabolism, 2000, 11, 184-188.	7.1	201
29	Prevention of diseases after menopause. Climacteric, 2014, 17, 540-556.	2.4	197
30	Testosterone Effects on the Breast: Implications for Testosterone Therapy for Women. Endocrine Reviews, 2004, 25, 374-388.	20.1	196
31	Estrogen and Progestin Compared with Simvastatin for Hypercholesterolemia in Postmenopausal Women. New England Journal of Medicine, 1997, 337, 595-601.	27.0	189
32	Testosterone in womenâ€"the clinical significance. Lancet Diabetes and Endocrinology,the, 2015, 3, 980-992.	11.4	181
33	Users of oestrogen replacement therapy have more knee cartilage than non-users. Annals of the Rheumatic Diseases, 2001, 60, 332-336.	0.9	177
34	The International Society for the Study of Women's Sexual Health Process of Care for Management of Hypoactive Sexual Desire Disorder in Women. Mayo Clinic Proceedings, 2018, 93, 467-487.	3.0	166
35	PREMATURE OVARIAN FAILURE. Endocrinology and Metabolism Clinics of North America, 1998, 27, 989-1006.	3.2	164
36	Testosterone influences libido and well being in women. Trends in Endocrinology and Metabolism, 2001, 12, 33-37.	7.1	157

#	Article	IF	CITATIONS
37	Evidence That Parenteral Testosterone Therapy May Improve Endothelium-Dependent and -Independent Vasodilation in Postmenopausal Women Already Receiving Estrogen. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 158-161.	3.6	153
38	Testosterone treatment of HSDD in naturally menopausal women: the ADORE study. Climacteric, 2010, 13, 121-131.	2.4	152
39	Sexual Function After Breast Cancer. Journal of Sexual Medicine, 2011, 8, 294-302.	0.6	150
40	Local estrogen biosynthesis in males and females Endocrine-Related Cancer, 1999, 6, 131-137.	3.1	147
41	Global Consensus Position Statement on the Use of Testosterone Therapy for Women. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 4660-4666.	3.6	147
42	Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women. Menopause, 2006, 13, 770-779.	2.0	146
43	Effects of estradiol with and without testosterone on body composition and relationships with lipids in postmenopausal women. Menopause, 2000, 7, 395-401.	2.0	145
44	Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes and Endocrinology, the, 2019, 7, 754-766.	11.4	140
45	Androgens in women. Journal of Steroid Biochemistry and Molecular Biology, 2003, 85, 363-366.	2.5	136
46	Understanding variation in prevalence estimates of polycystic ovary syndrome: a systematic review and meta-analysis. Human Reproduction Update, 2018, 24, 694-709.	10.8	134
47	Safety and Efficacy of a Testosterone Metered-Dose Transdermal Spray for Treating Decreased Sexual Satisfaction in Premenopausal Women. Annals of Internal Medicine, 2008, 148, 569.	3.9	131
48	DHEA Replacement for Postmenopausal Women. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 1642-1653.	3.6	131
49	Prevalence and incidence of urinary incontinence in women: Review of the literature and investigation of methodological issues. International Journal of Urology, 2008, 15, 230-234.	1.0	124
50	Minireview: Aromatase and the Regulation of Estrogen Biosynthesis-Some New Perspectives. Endocrinology, 2001, 142, 4589-4594.	2.8	121
51	Treatment of menopausal symptoms: what shall we do now?. Lancet, The, 2005, 366, 409-421.	13.7	116
52	Factors affecting progression of knee cartilage defects in normal subjects over 2 years. Rheumatology, 2006, 45, 79-84.	1.9	116
53	New Markers for Cardiovascular Disease Risk in Women: Impact of Endogenous Estrogen Status and Exogenous Postmenopausal Hormone Therapy. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 2470-2478.	3.6	112
54	Androgen Replacement in Women: A Commentary. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 1886-1891.	3.6	111

#	Article	IF	Citations
55	INHIBIN GENE EXPRESSION IN THE HUMAN CORPUS LUTEUM. Journal of Endocrinology, 1987, 115, R21-R23.	2.6	107
56	A pilot study of hormone modulation as a new treatment for mania in women with bipolar affective disorder. Psychoneuroendocrinology, 2006, 31, 543-547.	2.7	106
57	Piloting the effective therapeutic dose of adjunctive selective estrogen receptor modulator treatment in postmenopausal women with schizophrenia. Psychoneuroendocrinology, 2010, 35, 1142-1147.	2.7	106
58	The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women's Sexual Health (ISSWSH) expert consensus panel review. Menopause, 2018, 25, 837-847.	2.0	105
59	Testosterone for peri and postmenopausal women. The Cochrane Library, 2005, , CD004509.	2.8	104
60	FSD PHARMACOTHERAPY: Tibolone and Transdermal E2/NETA for the Treatment of Female Sexual Dysfunction in Naturally Menopausal Women: Results of a Randomized Active-Controlled Trial. Journal of Sexual Medicine, 2008, 5, 646-656.	0.6	102
61	Clinical review 82: Androgens and the postmenopausal woman Journal of Clinical Endocrinology and Metabolism, 1996, 81, 2759-2763.	3.6	100
62	Endocrine Aspects of Female Sexual Dysfunction. Journal of Sexual Medicine, 2004, 1, 82-86.	0.6	98
63	Dehydroepiandrosterone Sulfate Levels Are Associated with More Favorable Cognitive Function in Women. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 801-808.	3.6	95
64	Estrogen regulates development of the somatic cell phenotype in the eutherian ovary. FASEB Journal, 2002, 16, 1389-1397.	0.5	93
65	Greater superior than inferior parietal lobule activation with increasing rotation angle during mental rotation: An fMRI study. Neuropsychologia, 2010, 48, 529-535.	1.6	93
66	Efficacy and Safety of Testosterone in the Management of Hypoactive Sexual Desire Disorder in Postmenopausal Women. Journal of Sexual Medicine, 2012, 9, 1134-1148.	0.6	91
67	Moderate to severe vasomotor and sexual symptoms remain problematic for women aged 60 to 65 years. Menopause, 2015, 22, 694-701.	2.0	90
68	The use of hormone therapy for the maintenance of urogynecological and sexual health post WHI. Climacteric, 2012, 15, 267-274.	2.4	89
69	Managing Menopausal Symptoms and Associated Clinical Issues in Breast Cancer Survivors. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3647-3661.	3.6	89
70	Sexual well-being after menopause: An International Menopause Society White Paper. Climacteric, 2018, 21, 415-427.	2.4	89
71	Total cholesterol and triglycerides are associated with the development of new bone marrow lesions in asymptomatic middle-aged women - a prospective cohort study. Arthritis Research and Therapy, 2009, 11, R181.	3.5	87
72	DHEA therapy for women: effect on sexual function and wellbeing. Human Reproduction Update, 2007, 13, 239-248.	10.8	86

#	Article	IF	Citations
73	Profile of Female Sexual Function: a patient-based, international, psychometric instrument for the assessment of hypoactive sexual desire in oophorectomized women. Menopause, 2004, 11, 474-483.	2.0	85
74	Endocrine Aspects of Women's Sexual Function. Journal of Sexual Medicine, 2010, 7, 561-585.	0.6	85
75	Androgens and Female Sexual Function and Dysfunctionâ€"Findings From the Fourth International Consultation of Sexual Medicine. Journal of Sexual Medicine, 2016, 13, 168-178.	0.6	85
76	The effects of tibolone on mood and libido. Menopause, 2002, 9, 162-170.	2.0	81
77	A study of the prevalence and associations of subchondral bone marrow lesions in the knees of healthy, middle-aged women. Osteoarthritis and Cartilage, 2007, 15, 1437-1442.	1.3	81
78	Hormone replacement therapy: current controversies. Clinical Endocrinology, 2003, 58, 249-261.	2.4	79
79	DHEA for postmenopausal women: A review of the evidence. Maturitas, 2010, 66, 172-179.	2.4	79
80	Inhibin a-subunit gene expression in the ovaries of immature female rats is stimulated by pregnant mare serum gonadotrophin. Biochemical and Biophysical Research Communications, 1986, 138, 1191-1195.	2.1	78
81	Age-specific prevalence of, and factors associated with, different types of urinary incontinence in community-dwelling Australian women assessed with a validated questionnaire. Maturitas, 2009, 62, 134-139.	2.4	78
82	Effects of aromatase inhibition on sexual function and well-being in postmenopausal women treated with testosterone: a randomized, placebo-controlled trial. Menopause, 2006, 13, 37-45.	2.0	76
83	Androgens During the Reproductive Years: What Is Normal for Women?. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5382-5392.	3.6	76
84	Phytoestrogens and breast cancer in postmenopausal women: a case control study. Menopause, 2000, 7, 289-296.	2.0	75
85	Bone marrow lesions predict increase in knee cartilage defects and loss of cartilage volume in middle-aged women without knee pain over 2 years. Annals of the Rheumatic Diseases, 2009, 68, 850-855.	0.9	75
86	The association between vasomotor symptoms and depression during perimenopause: A systematic review. Maturitas, 2014, 77, 111-117.	2.4	75
87	Role of Estrogens and Estrogen-Like Compounds in Female Sexual Function and Dysfunction. Journal of Sexual Medicine, 2016, 13, 305-316.	0.6	75
88	Effect of Adjunctive Raloxifene Therapy on Severity of Refractory Schizophrenia in Women. JAMA Psychiatry, 2016, 73, 947.	11.0	74
89	Clinical review 82: Androgens and the postmenopausal woman. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 2759-2763.	3.6	74
90	Well-being, health-related quality of life and cardiovascular disease risk profile in women with subclinical thyroid disease? a community-based study. Clinical Endocrinology, 2007, 66, 070210034307001-???.	2.4	73

#	Article	IF	CITATIONS
91	Prevalence and Predictors of Low Sexual Desire, Sexually Related Personal Distress, and Hypoactive Sexual Desire Dysfunction in a Community-Based Sample of Midlife Women. Journal of Sexual Medicine, 2017, 14, 675-686.	0.6	72
92	The relationship between body composition and knee cartilage volume in healthy, middle-aged subjects. Arthritis and Rheumatism, 2005, 52, 461-467.	6.7	70
93	The effects of Chinese medicinal herbs on postmenopausal vasomotor symptoms of Australian women. Medical Journal of Australia, 2001, 174, 68-71.	1.7	69
94	Sexual Function in Well Women: Stratification by Sexual Satisfaction, Hormone Use, and Menopause Status. Journal of Sexual Medicine, 2008, 5, 1214-1222.	0.6	68
95	The effect of the knee adduction moment on tibial cartilage volume and bone size in healthy women. British Journal of Rheumatology, 2003, 43, 311-314.	2.3	67
96	When to suspect androgen deficiency other than at menopause 11Reprints will not be available Fertility and Sterility, 2002, 77, 68-71.	1.0	66
97	Adipose aromatase gene expression is greater in older women and is unaffected by postmenopausal estrogen therapy. Menopause, 2005, 12, 210-215.	2.0	66
98	A Practitioner's Toolkit for Managing the Menopause. Climacteric, 2014, 17, 564-579.	2.4	64
99	Tibial plateau size is related to grade of joint space narrowing and osteophytes in healthy women and in women with osteoarthritis. Annals of the Rheumatic Diseases, 2005, 64, 1033-1037.	0.9	62
100	Factors influencing longitudinal change in knee cartilage volume measured from magnetic resonance imaging in healthy men. Annals of the Rheumatic Diseases, 2005, 64, 1038-1042.	0.9	62
101	Differential expression of factors involved in fat metabolism with age and the menopause transition. Maturitas, 2005, 51, 299-306.	2.4	62
102	Endogenous androgen levels and cardiovascular risk profile in women across the adult life span. Menopause, 2007, 14, 630-638.	2.0	62
103	Androgen insufficiency in women: diagnostic and therapeutic implications. Human Reproduction Update, 2004, 10, 421-432.	10.8	61
104	Negative beliefs about low back pain are associated with high pain intensity and high level disability in community-based women. BMC Musculoskeletal Disorders, 2008, 9, 148.	1.9	59
105	Prevalence of menopausal symptoms in Asian midlife women: a systematic review. Climacteric, 2015, 18, 157-176.	2.4	58
106	Tibial cartilage volume change in healthy postmenopausal women: a longitudinal study. Annals of the Rheumatic Diseases, 2004, 63, 444-449.	0.9	57
107	The therapeutic use of androgens in women. Journal of Steroid Biochemistry and Molecular Biology, 1999, 69, 177-184.	2.5	56
108	Vaginal DHEA to treat menopause related atrophy: A review of the evidence. Maturitas, 2011, 70, 22-25.	2.4	56

#	Article	IF	Citations
109	Endogenous androgen levels and well-being: differences between premenopausal and postmenopausal women. Menopause, 2006, 13, 65-71.	2.0	53
110	Static knee alignment is associated with the risk of unicompartmental knee cartilage defects. Journal of Orthopaedic Research, 2008, 26, 225-230.	2.3	53
111	Change to Either a Nonandrogenic or Androgenic Progestin-Containing Oral Contraceptive Preparation is Associated with Improved Sexual Function in Women with Oral Contraceptive-Associated Sexual Dysfunction. Journal of Sexual Medicine, 2013, 10, 3069-3079.	0.6	53
112	Phytoestrogen therapy for menopausal symptoms?. BMJ: British Medical Journal, 2001, 323, 354-355.	2.3	52
113	Global Consensus Position Statement on the Use of Testosterone Therapy for Women. Climacteric, 2019, 22, 429-434.	2.4	50
114	Osteoarthritis and the postmenopausal woman: Epidemiological, magnetic resonance imaging, and radiological findings. Seminars in Arthritis and Rheumatism, 2004, 34, 631-636.	3.4	49
115	The safety of 52 weeks of oral DHEA therapy for postmenopausal women. Maturitas, 2009, 63, 240-245.	2.4	49
116	Moderate-severely bothersome vasomotor symptoms are associated with lowered psychological general wellbeing in women at midlife. Maturitas, 2015, 81, 487-492.	2.4	49
117	Menopausal vasomotor symptoms are associated with poor self-assessed work ability. Maturitas, 2016, 87, 33-39.	2.4	49
118	Phytoestrogens in health and disease. Endocrine Reviews, 1999, 54, 185-210; discussion 210-1.	6.7	49
119	Menopausal symptoms in breast cancer survivors nearly 6 years after diagnosis. Menopause, 2014, 21, 1075-1081.	2.0	48
120	Sexual Function, Incontinence, and Wellbeing in Women after Rectal Cancerâ€"A Review of the Evidence. Journal of Sexual Medicine, 2012, 9, 2749-2758.	0.6	46
121	Moderate–Severe Vasomotor Symptoms Are Associated with Moderate–Severe Depressive Symptoms. Journal of Women's Health, 2017, 26, 712-718.	3.3	46
122	A Randomized Trial of Oral DHEA Treatment for Sexual Function, Well-Being, and Menopausal Symptoms in Postmenopausal Women with Low Libido. Journal of Sexual Medicine, 2009, 6, 2579-2590.	0.6	44
123	Premature ovarian failure. Maturitas, 1996, 23, 1-8.	2.4	43
124	Prevalence of fecal incontinence and its relationship with urinary incontinence in women living in the community. Menopause, 2011, 18, 685-689.	2.0	43
125	Testosterone improves verbal learning and memory in postmenopausal women: Results from a pilot study. Maturitas, 2011, 70, 307-311.	2.4	42
126	Modes of Infant Feeding and the Occurrence of Coughing/Wheezing in the First Year of Life. Journal of Human Lactation, 2013, 29, 71-80.	1.6	42

#	Article	IF	Citations
127	Intravaginal Testosterone Improves Sexual Satisfaction and Vaginal Symptoms Associated With Aromatase Inhibitors. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 4146-4154.	3.6	42
128	The clinical use of androgens in female sexual disorders. Journal of Sex and Marital Therapy, 1998, 24, 153-163.	1.5	41
129	Testosterone insufficiency in women: fact or fiction?. World Journal of Urology, 2002, 20, 106-110.	2.2	41
130	Testosterone aromatization and cognition in women: a randomized, placebo-controlled trial. Menopause, 2006, 13, 600-608.	2.0	41
131	Static knee alignment and its association with radiographic knee osteoarthritis. Osteoarthritis and Cartilage, 2006, 14, 958-962.	1.3	41
132	Foot rotationâ€"A potential target to modify the knee adduction moment. Journal of Science and Medicine in Sport, 2006, 9, 67-71.	1.3	41
133	Symptomatic pelvic floor disorders in community-dwelling older Australian women. Maturitas, 2016, 85, 34-41.	2.4	41
134	Vasomotor and sexual symptoms in older Australian women: a cross-sectional study. Fertility and Sterility, 2016, 105, 149-155.e1.	1.0	41
135	Androgen Replacement in Women: A Commentary. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 1886-1891.	3.6	41
136	Urinary Incontinence in Young Nulligravid Women. Annals of Internal Medicine, 2012, 157, 87.	3.9	40
137	International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. Journal of Sexual Medicine, 2021, 18, 849-867.	0.6	40
138	Effects of tibolone and raloxifene on bone mineral density in osteopenic postmenopausal women. Osteoporosis International, 2008, 19, 1153-1160.	3.1	39
139	Cardiovascular and cancer safety of testosterone in women. Current Opinion in Endocrinology, Diabetes and Obesity, 2011, 18, 198-203.	2.3	39
140	Evidence That Parenteral Testosterone Therapy May Improve Endothelium-Dependent and -Independent Vasodilation in Postmenopausal Women Already Receiving Estrogen. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 158-161.	3.6	39
141	The Incidence of Invasive Breast Cancer Among Women Prescribed Testosterone for Low Libido. Journal of Sexual Medicine, 2009, 6, 1850-1856.	0.6	38
142	Compartment differences in knee cartilage volume in healthy adults. Journal of Rheumatology, 2002, 29, 554-6.	2.0	38
143	Postmenopausal testosterone therapy and breast cancer risk. Maturitas, 2004, 49, 267-275.	2.4	37
144	Urinary incontinence is associated with lower psychological general well-being in community-dwelling women. Menopause, 2010, 17, 332-337.	2.0	37

#	Article	lF	Citations
145	Androgenic hormones and aging â€" The link with female sexual function. Hormones and Behavior, 2011, 59, 745-753.	2.1	37
146	Hormonal therapies for new onset and relapsed depression during perimenopause. Maturitas, 2012, 73, 127-133.	2.4	37
147	Testosterone and Estrone Increase From the Age of 70 Years: Findings From the Sex Hormones in Older Women Study. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 6291-6300.	3.6	37
148	Treating menopause â€" MHT and beyond. Nature Reviews Endocrinology, 2022, 18, 490-502.	9.6	37
149	Transition from estrogen therapy to raloxifene in postmenopausal women: effects on treatment satisfaction and the endometrium—a pilot study. Menopause, 2004, 11, 167-175.	2.0	36
150	The Effect of Transdermal Testosterone on Mammographic Density in Postmenopausal Women Not Receiving Systemic Estrogen Therapy. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 4907-4913.	3.6	36
151	Testosterone Improves Antidepressant-Emergent Loss of Libido in Women: Findings from a Randomized, Double-Blind, Placebo-Controlled Trial. Journal of Sexual Medicine, 2014, 11, 831-839.	0.6	36
152	Obesity is associated with a poorer prognosis in women with hormone receptor positive breast cancer. Maturitas, 2014, 79, 279-286.	2.4	36
153	"Reprint of―Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas, 2008, 61, 17-26.	2.4	35
154	A pragmatic approach to the classification of menopausal status for community-based research. Menopause, 2008, 15, 978-983.	2.0	35
155	Incidence of Total Knee and Hip Replacement for Osteoarthritis in Relation to Circulating Sex Steroid Hormone Concentrations in Women. Arthritis and Rheumatology, 2014, 66, 2144-2151.	5.6	35
156	REVIEW: Female Sexual Satisfaction and Pharmaceutical Intervention: A Critical Review of the Drug Intervention Studies in Female Sexual Dysfunction. Journal of Sexual Medicine, 2006, 3, 763-777.	0.6	34
157	Awareness of breast cancer and barriers to breast screening uptake in Bangladesh: A population based survey. Maturitas, 2016, 84, 68-74.	2.4	34
158	Pharmacokinetics and Acute Safety of Inhaled Testosterone in Postmenopausal Women. Journal of Clinical Pharmacology, 2005, 45, 177-184.	2.0	33
159	Postmenopausal hormone therapy: from monkey glands to transdermal patches. Journal of Endocrinology, 2005, 185, 207-222.	2.6	33
160	Factors affecting patella cartilage and bone in middle-aged women. Arthritis and Rheumatism, 2007, 57, 272-278.	6.7	33
161	Use of a cancer registry is preferable to a direct-to-community approach for recruitment to a cohort study of wellbeing in women newly diagnosed with invasive breast cancer. BMC Cancer, 2008, 8, 126.	2.6	33
162	Androgens in postmenopausal women: a review. Menopause, 2017, 24, 970-979.	2.0	33

#	Article	IF	CITATIONS
163	A systematic review of intravaginal testosterone for the treatment of vulvovaginal atrophy. Menopause, 2018, 25, 704-709.	2.0	33
164	The cross-sectional relationship between fortnightly exercise and knee cartilage properties in healthy adult women in midlife. Menopause, 2007, 14, 830-834.	2.0	32
165	The determinants of change in patella cartilage volumea cohort study of healthy middle-aged women. Rheumatology, 2008, 47, 1426-1429.	1.9	32
166	Hypoactive sexual desire dysfunction in community-dwelling older women. Menopause, 2017, 24, 391-399.	2.0	32
167	Pregnant Mare's Serum Gonadotropin Stimulates Inhibin Subunit Gene Expression in the Immature Rat Ovary: Dose Response Characteristics and Relationships to Serum Gonadotropins, Inhibin, and Ovarian Steroid Content*. Endocrinology, 1988, 123, 2399-2407.	2.8	31
168	Androgen treatment of postmenopausal women. Journal of Steroid Biochemistry and Molecular Biology, 2014, 142, 107-114.	2.5	31
169	Hormones and Female Sexual Dysfunction: Beyond Estrogens and Androgensâ€"Findings From the Fourth International Consultation on Sexual Medicine. Journal of Sexual Medicine, 2016, 13, 283-290.	0.6	31
170	Persistent breast pain 5\AA years after treatment of invasive breast cancer is largely unexplained by factors associated with treatment. Journal of Cancer Survivorship, 2014, 8, 1-8.	2.9	30
171	Low use of effective and safe therapies for moderate to severe menopausal symptoms. Menopause, 2016, 23, 11-17.	2.0	30
172	Associations between androgens and sexual function in premenopausal women: a cross-sectional study. Lancet Diabetes and Endocrinology, the, 2020, 8, 693-702.	11.4	30
173	Androgen treatment in women. Medical Journal of Australia, 1999, 170, 545-549.	1.7	29
174	Preliminary indication of a high prevalence of polycystic ovary syndrome in indigenous Australian women. Gynecological Endocrinology, 2002, 16, 443-446.	1.7	29
175	The Relationship between Endogenous Testosterone, Preandrogens, and Sex Hormone Binding Globulin and Knee Joint Structure in Women at Midlife. Seminars in Arthritis and Rheumatism, 2007, 37, 56-62.	3.4	29
176	Breast cancer survivors' beliefs about the causes of breast cancer. Psycho-Oncology, 2012, 21, 724-729.	2.3	29
177	Testosterone and Sexual Desire in Women. Journal of Sex Education and Therapy, 2000, 25, 25-32.	0.3	28
178	The contribution of SHBG to the variation in HOMAâ€IR is not dependent on endogenous oestrogen or androgen levels in postmenopausal women. Clinical Endocrinology, 2012, 77, 541-547.	2.4	28
179	The prevalence of symptomatic pelvic floor disorders in women in Bangladesh. Climacteric, 2016, 19, 558-564.	2.4	28
180	Factors affecting tibial plateau expansion in healthy women over 2.5 years: a longitudinal study. Osteoarthritis and Cartilage, 2006, 14, 1258-1264.	1.3	27

#	Article	IF	Citations
181	Incidence and Resolution Rates of Different Types of Urinary Incontinence in Women: Findings From a Cohort Study. Journal of Urology, 2011, 185, 1331-1337.	0.4	27
182	Androgen therapy in women, beyond libido. Climacteric, 2013, 16, 18-24.	2.4	27
183	Phytoestrogens in Clinical Practice. Integrative Medicine: Integrating Conventional and Alternative Medicine, 1998, 1, 27-34.	0.1	26
184	Measurement of total testosterone in women: comparison of a direct radioimmunoassay versus radioimmunoassay after organic solvent extraction and celite column partition chromatography. Fertility and Sterility, 2005, 84, 1698-1704.	1.0	26
185	Transdermal testosterone improves verbal learning and memory in postmenopausal women not on oestrogen therapy. Clinical Endocrinology, 2014, 81, 621-628.	2.4	26
186	A four week randomised control trial of adjunctive medroxyprogesterone and tamoxifen in women with mania. Psychoneuroendocrinology, 2014, 43, 52-61.	2.7	26
187	The Associations Between the Dominant and Nondominant Peak External Knee Adductor Moments During Gait in Healthy Subjects: Evidence for Symmetry. Archives of Physical Medicine and Rehabilitation, 2009, 90, 320-324.	0.9	25
188	Testosterone for Poor Ovarian Responders: Lessons From Ovarian Physiology. Reproductive Sciences, 2018, 25, 980-982.	2.5	25
189	Prevalence of menopausal symptoms in Australian women at midlife: a systematic review. Climacteric, 2014, 17, 529-539.	2.4	24
190	Vasomotor symptoms in women in Asia appear comparable with women in Western countries: a systematic review. Menopause, 2017, 24, 1313-1322.	2.0	24
191	Responses to the Proposed DSM-V Changes. Journal of Sexual Medicine, 2010, 7, 1998-2014.	0.6	23
192	An update on the pharmacological management of female sexual dysfunction. Expert Opinion on Pharmacotherapy, 2012, 13, 2131-2142.	1.8	23
193	Breast reconstruction following mastectomy for invasive breast cancer is strongly influenced by demographic factors in women in Victoria, Australia. Breast, 2012, 21, 394-400.	2.2	23
194	Aromatase Inhibitors Are Associated with Low Sexual Desire Causing Distress and Fecal Incontinence in Women: An Observational Study. Journal of Sexual Medicine, 2017, 14, 1566-1574.	0.6	23
195	The rationale for physiological testosterone replacement in women. Bailliere's Clinical Endocrinology and Metabolism, 1998, 12, 391-405.	1.0	22
196	Postmenopausal Hormone-Replacement Therapy. New England Journal of Medicine, 2002, 346, 63-65.	27.0	22
197	Association between knee cartilage volume and bone mineral density in older adults without osteoarthritis. Rheumatology, 2004, 43, 765-769.	1.9	22
198	Fatty Acids in Breast Milk Associated with Asthma-Like Symptoms and Atopy in Infancy: A Longitudinal Study. Journal of Asthma, 2012, 49, 926-934.	1.7	22

#	Article	IF	CITATIONS
199	Effects of testosterone on visuospatial function and verbal fluency in postmenopausal women. Menopause, 2014, 21, 410-414.	2.0	22
200	Lack of Understanding of Cervical Cancer and Screening Is the Leading Barrier to Screening Uptake in Women at Midlife in Bangladesh: Population-Based Cross-Sectional Survey. Oncologist, 2015, 20, 1386-1392.	3.7	22
201	Vasomotor symptoms and urogenital atrophy in older women: a systematic review. Climacteric, 2015, 18, 112-120.	2.4	22
202	Prevalence and severity of vasomotor symptoms and joint pain in women at midlife in Bangladesh: a population-based survey. Menopause, 2016, 23, 731-739.	2.0	22
203	Global Consensus Position Statement on the Use of Testosterone Therapy for Women. Journal of Sexual Medicine, 2019, 16, 1331-1337.	0.6	22
204	The prevalence of sexual dysfunctions and sexually related distress in young women: a cross-sectional survey. Fertility and Sterility, 2020, 113, 426-434.	1.0	22
205	International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. Journal of Women's Health, 2021, 30, 474-491.	3.3	22
206	Another role highlighted for estrogens in the male: Sexual behavior. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 14038-14040.	7.1	21
207	High sensitivity C-reactive protein is associated with lower tibial cartilage volume but not lower patella cartilage volume in healthy women at mid-life. Arthritis Research and Therapy, 2008, 10, R27.	3.5	21
208	A core outcome set for vasomotor symptoms associated with menopause: the COMMA (Core Outcomes) Tj ETC	0q0 <u>0</u> 0 rg	BT /Overlock
209	Association between meniscal tears and the peak external knee adduction moment and foot rotation during level walking in postmenopausal women without knee osteoarthritis: a cross-sectional study. Arthritis Research and Therapy, 2008, 10, R58.	3.5	20
210	Understanding discontinuation of oral adjuvant endocrine therapy by women with hormone receptor–positive invasive breast cancer nearly 4 years from diagnosis. Menopause, 2013, 20, 15-21.	2.0	20
211	Pharmacokinetics of a transdermal testosterone cream in healthy postmenopausal women. Menopause, 2015, 22, 44-49.	2.0	20
212	The benefits of adding metformin to tamoxifen to protect the endometrium—A randomized placeboâ€controlled trial. Clinical Endocrinology, 2018, 89, 605-612.	2.4	20
213	Underlying Breast Cancer Risk and Menopausal Hormone Therapy. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2299-e2307.	3.6	20
214	Validity and cultural equivalence of the standard Greene Climacteric Scale in Hong Kong. Menopause, 2010, 17, 630-635.	2.0	20
215	What is the Rationale for Androgen Therapy for Women?. Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders, 2003, 2, 77-84.	1.8	19
216	Effects of tibolone and raloxifene on health-related quality of life and sexual function. Maturitas, 2007, 58, 164-173.	2.4	19

#	Article	IF	Citations
217	Assessing Sexual Function in Well Women: Validity and Reliability of the Monash Women's Health Program Female Sexual Satisfaction Questionnaire. Journal of Sexual Medicine, 2008, 5, 2575-2586.	0.6	19
218	Meniscal tear and increased tibial plateau bone area in healthy post-menopausal women. Osteoarthritis and Cartilage, 2008, 16, 268-271.	1.3	19
219	Management strategies in SSRI-associated sexual dysfunction in women at midlife. Climacteric, 2012, 15, 306-316.	2.4	19
220	Menopause, lung function and obstructive lung disease outcomes: a systematic review. Climacteric, 2018, 21, 3-12.	2.4	19
221	Negative beliefs about back pain are associated with persistent, high levels of low back disability in community-based women. Menopause, 2018, 25, 977-984.	2.0	19
222	Ultrasensitive Serum Estradiol Measurement by Liquid Chromatography-Mass Spectrometry in Postmenopausal Women and Mice. Journal of the Endocrine Society, 2020, 4, bvaa086.	0.2	19
223	A core outcome set for genitourinary symptoms associated with menopause: the COMMA (Core) Tj ETQq $1\ 1\ 0.7$	843]4 rgt 2.0	3T <u>/</u> 9verlock
224	The role of androgen therapy. Best Practice and Research in Clinical Endocrinology and Metabolism, 2003, 17, 165-175.	4.7	18
225	Aminina Nud Mulumuluna ("You Gotta Look After Yourselfâ€): Evaluation of the use of traditional art in health promotion for Aboriginal people in the Kimberley region of Western Australia. Australian Psychologist, 2004, 39, 107-113.	1.6	18
226	Endogenous estrogen and androgen levels are not independent predictors of lipid levels in postmenopausal women. Menopause, 2013, 20, 640-645.	2.0	18
227	Factors associated with magnetic resonance imaging defined patellar tendinopathy in community-based middle-aged women: a prospective cohort study. BMC Musculoskeletal Disorders, 2015, 16, 184.	1.9	18
228	The relationship between the knee adduction moment and knee pain in middle-aged women without radiographic osteoarthritis. Journal of Rheumatology, 2006, 33, 1845-8.	2.0	18
229	In-vivo dosimetry from total body irradiation patients (2000–2006): results and analysis. Australasian Physical and Engineering Sciences in Medicine, 2008, 31, 191-195.	1.3	17
230	Low back pain and disability in community-based women. Menopause, 2009, 16, 24-29.	2.0	17
231	Psychological well-being in a cohort of women with invasive breast cancer nearly 2Âyears after diagnosis. Supportive Care in Cancer, 2010, 18, 921-929.	2.2	17
232	Continuous-combined oral estradiol/drospirenone has no detrimental effect on cognitive performance and improves estrogen deficiency symptoms in early postmenopausal women. Menopause, 2013, 20, 1020-1026.	2.0	17
233	Effect of estrogen replacement therapy on patella cartilage in healthy women. Clinical and Experimental Rheumatology, 2003, 21, 79-82.	0.8	17
234	Use of androgens in postmenopausal women. Current Opinion in Obstetrics and Gynecology, 1997, 9, 177-180.	2.0	16

#	Article	IF	CITATIONS
235	Differing effects of low-dose estrogen–progestin therapy and pravastatin in postmenopausal hypercholesterolemic women. Climacteric, 2002, 5, 341-350.	2.4	16
236	Beyond human resource management in coâ€operatives. Cross Cultural Management, 2006, 13, 69-95.	1.1	16
237	Androgen therapy in women: What we think we know. Experimental Gerontology, 2007, 42, 457-462.	2.8	16
238	Use of complementary and alternative medicines for menopausal symptoms in Australian women aged 40–65 years. Medical Journal of Australia, 2015, 203, 146-146.	1.7	16
239	Metformin for overweight women at midlife: a double-blind, randomized, controlled trial. Climacteric, 2015, 18, 270-277.	2.4	16
240	Challenges in recruitment to an epidemiological study of young Australian women: the Grolloâ€Ruzzene Foundation Young Women's Health Study. Australian and New Zealand Journal of Public Health, 2019, 43, 131-136.	1.8	16
241	Analysis of variants in <i>GATA4</i> and <i>FOG2</i> / <i>ZFPM2</i> demonstrates benign contribution to 46,XY disorders of sex development. Molecular Genetics & Enomic Medicine, 2020, 8, e1095.	1.2	16
242	Do intracrine mechanisms regulate aromatase expression?. Journal of Steroid Biochemistry and Molecular Biology, 1999, 69, 447-452.	2.5	15
243	What Are "Normal―Testosterone Levels for Women?. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1842-1846.	3.6	15
244	Pharmacological Therapy for Female Sexual Dysfunction. Drugs, 2008, 68, 259-264.	10.9	15
245	Lymphedema: experience of a cohort of women with breast cancer followed for 4Âyears after diagnosis in Victoria, Australia. Supportive Care in Cancer, 2013, 21, 2017-2024.	2.2	15
246	Effects of testosterone therapy for women: a systematic review and meta-analysis protocol. Systematic Reviews, 2019, 8, 19.	5.3	15
247	Australian women's understanding of menopause and its consequences: a qualitative study. Climacteric, 2020, 23, 622-628.	2.4	15
248	Associations between blood sex steroid concentrations and risk of major adverse cardiovascular events in healthy older women in Australia: a prospective cohort substudy of the ASPREE trial. The Lancet Healthy Longevity, 2022, 3, e109-e118.	4.6	15
249	Concurrent use of simvastatin and estrogen-progestin therapy compared with each therapy alone for hypercholesterolemia in postmenopausal women. Climacteric, 1999, 2, 181-188.	2.4	14
250	What is the clinical and ethical importance of incidental abnormalities found by knee MRI?. Arthritis Research and Therapy, 2008, 10, R18.	3.5	14
251	Use of complementary and alternative therapy by women in the first 2 years after diagnosis and treatment of invasive breast cancer. Menopause, 2010, 17, 1004-1009.	2.0	14
252	Changes in patterns of use of cigarettes and alcohol in women after a first diagnosis of invasive breast cancer: a cohort study of women from Victoria, Australia. Supportive Care in Cancer, 2012, 20, 783-789.	2,2	14

#	Article	IF	Citations
253	Moderate to severe vasomotor and sexual symptoms remain problematic for women aged 60 to 65 years. Menopause, 2018, 25, 1331-1338.	2.0	14
254	Estrone Is a Strong Predictor of Circulating Estradiol in Women Age 70 Years and Older. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3348-e3354.	3.6	14
255	Sagittal plane movement at the tibiofemoral joint influences patellofemoral joint structure in healthy adult women. Osteoarthritis and Cartilage, 2006, 14, 331-336.	1.3	13
256	Simplifying screening for osteoporosis in Australian primary care. Menopause, 2011, 18, 53-59.	2.0	13
257	Types of urinary incontinence in Bangladeshi women at midlife: Prevalence and risk factors. Maturitas, 2018, 116, 18-23.	2.4	13
258	Hormonal contraceptive use in Australian women: Who is using what?. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2019, 59, 717-724.	1.0	13
259	A double exposed portal image comparison between electronic portal imaging hard copies and port films in radiation therapy treatment setup confirmation to determine its clinical application in a radiotherapy center. International Journal of Radiation Oncology Biology Physics, 2001, 49, 191-198.	0.8	12
260	Lack of Knowledge of Hormone Receptor Status and Use of Endocrine Therapy in Invasive Breast Cancer. Journal of Women's Health, 2009, 18, 1975-1980.	3.3	12
261	Are low levels of low back pain intensity and disability associated with reduced well-being in community-based women?. Climacteric, 2009, 12, 266-275.	2.4	12
262	The Natural History of Bone Marrow Lesions in Community-Based Middle-Aged Women Without Clinical Knee Osteoarthritis. Seminars in Arthritis and Rheumatism, 2009, 39, 213-217.	3.4	12
263	Prevalence of sexual symptoms in relation to menopause in women in Asia: a systematic review. Menopause, 2018, 25, 231-238.	2.0	12
264	Global Consensus Position Statement on the use of Testosterone Therapy for Women. Maturitas, 2019, 128, 89-93.	2.4	12
265	Workshop on normal reference ranges for estradiol in postmenopausal women, September 2019, Chicago, Illinois. Menopause, 2020, 27, 614-624.	2.0	12
266	Depressive symptoms and their risk factors in midlife women in the Middle East: a systematic review. Climacteric, 2018, 21, 13-21.	2.4	11
267	Bothersome menopausal symptoms amongst postmenopausal Iranian women. Climacteric, 2018, 21, 586-593.	2.4	11
268	Substituting serum anti-M \tilde{A}^{1} / 4 llerian hormone for polycystic ovary morphology increases the number of women diagnosed with polycystic ovary syndrome: a community-based cross-sectional study. Human Reproduction, 2021, 37, 109-118.	0.9	11
269	Risks of Postmenopausal Hormone ReplacementHormone Replacement Following Early Menopause. JAMA - Journal of the American Medical Association, 2002, 288, 2819.	7.4	10
270	Homocysteine, estrogen and cognitive decline. Climacteric, 2006, 9, 77-87.	2.4	10

#	Article	IF	Citations
271	Improved bleeding profile and tolerability of tibolone versus transdermal E2/NETA treatment in postmenopausal women with female sexual dysfunction. Climacteric, 2009, 12, 114-121.	2.4	10
272	Bangladesh Midlife Women's Health Study (BMWHS): Methods, challenges and experiences. Maturitas, 2015, 80, 89-94.	2.4	10
273	Poor general health and lower levels of vitality are associated with persistent, high-intensity low back pain and disability in community-based women: A prospective cohort study. Maturitas, 2018, 113, 7-12.	2.4	10
274	The Kupperman Index undressed. Maturitas, 2019, 126, 90-91.	2.4	10
275	Exogenous Testosterone Does Not Influence 11-Oxygenated C19 Steroid Concentrations in Healthy Postmenopausal Women. Journal of the Endocrine Society, 2019, 3, 670-677.	0.2	10
276	Prevalence of Low Sexual Desire with Associated Distress Across the Adult Life Span: An Australian Cross-Sectional Study. Journal of Sexual Medicine, 2020, 17, 1885-1895.	0.6	10
277	Distribution of Body Hair in Young Australian Women and Associations With Serum Androgen Concentrations. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 1186-1195.	3.6	10
278	Longitudinal changes over three years in sex steroid hormone levels in women aged 70Âyears and over. Clinical Endocrinology, 2021, 94, 443-448.	2.4	10
279	Use of community-based reference ranges to estimate the prevalence of polycystic ovary syndrome by the recognised diagnostic criteria, a cross-sectional study. Human Reproduction, 2021, 36, 1611-1620.	0.9	10
280	Health-care providers' views of menopause and its management: a qualitative study. Climacteric, 2021, 24, 612-617.	2.4	10
281	Differing effects of low-dose estrogen-progestin therapy and pravastatin in postmenopausal hypercholesterolemic women. Climacteric, 2002, 5, 341-50.	2.4	10
282	The role of androgen therapy. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2002, 16, 383-393.	2.8	9
283	Climacteric symptoms among indigenous Australian women and a model for the use of culturally relevant art in health promotion. Menopause, 2003, 10, 345-351.	2.0	9
284	Intranasal versus transdermal matrix oestrogen replacement in Australasian women. Maturitas, 2005, 51, 163-171.	2.4	9
285	The relationship between knowledge of family history and cancer characteristics at diagnosis in women newly-diagnosed with invasive breast cancer. Familial Cancer, 2009, 8, 299-305.	1.9	9
286	Understanding female sexual function. Menopause, 2009, 16, 425-426.	2.0	9
287	The prevalence of vitamin D deficiency and relationship with fracture risk in older women presenting in Australian general practice. Australasian Journal on Ageing, 2013, 32, 177-183.	0.9	9
288	Why Do the Clinical Sequelae of Estrogen Deficiency Affect Women More than Men?a. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 2214-2215.	3.6	9

#	Article	IF	Citations
289	Menopause: new therapies. Medical Journal of Australia, 2003, 178, 634-637.	1.7	8
290	Polycystic Ovarian Syndrome: the Next Cardiovascular Dilemma in Women?. Endocrinology and Metabolism Clinics of North America, 2006, 35, 611-631.	3.2	8
291	Vastus medialis cross-sectional area is associated with patella cartilage defects and bone volume in healthy women. Osteoarthritis and Cartilage, 2008, 16, 956-960.	1.3	8
292	Methodology and Challenges to Recruitment to a Randomized, Double-Blind, Placebo-Controlled Trial of Oral DHEA in Postmenopausal Women. Journal of Women's Health, 2008, 17, 1559-1565.	3.3	8
293	Effects of the route of estrogen administration on insulinlike growth factor-I, IGF binding protein-3, and insulin resistance in healthy postmenopausal women. Menopause, 2008, 15, 1065-1069.	2.0	8
294	Should women receive androgen replacement therapy, and if so, how?. Clinical Endocrinology, 2010, 72, 149-154.	2.4	8
295	Pregnancy-associated breast cancer and pregnancy following treatment for breast cancer, in a cohort of women from Victoria, Australia, with a first diagnosis of invasive breast cancer. Breast, 2013, 22, 980-985.	2.2	8
296	Patterns of use of oral adjuvant endocrine therapy in Australian breast cancer survivors 5 years from diagnosis. Menopause, 2013, 20, 721-726.	2.0	8
297	Women's expectations and experiences of hormone treatment for sexual dysfunction. Climacteric, 2014, 17, 674-681.	2.4	8
298	Minimal-trauma fracture in women with breast cancer surviving for at least 5Âyears from diagnosis. Osteoporosis International, 2015, 26, 795-800.	3.1	8
299	Determinants of change in patella cartilage volume in healthy subjects. Journal of Rheumatology, 2006, 33, 1658-61.	2.0	8
300	Sex and perimenopause. Australian Family Physician, 2011, 40, 274-8.	0.5	8
301	The effect of hypophysectomy on inhibin production by adult rat ovaries: Changes in ovarian inhibin gene expression and serum inhibin. Gynecological Endocrinology, 1988, 2, 223-232.	1.7	7
302	Postmenopausal hormone therapy: the pros and cons. Internal Medicine Journal, 2004, 34, 109-114.	0.8	7
303	Are the Endocrine Society's Clinical Practice Guidelines on Androgen Therapy in Women Misguided? A Commentary-Response. Journal of Sexual Medicine, 2007, 4, 1782-1783.	0.6	7
304	Drugs for the treatment of menopausal symptoms. Expert Opinion on Pharmacotherapy, 2010, 11, 1329-1341.	1.8	7
305	Association between urinary C-telopeptide fragments of type II collagen and knee structure in middle-aged women without clinical knee disease. Osteoarthritis and Cartilage, 2014, 22, 1136-1141.	1.3	7
306	Targeted assessment of fracture risk in women at midlife. Osteoporosis International, 2015, 26, 1705-1712.	3.1	7

#	Article	IF	Citations
307	Differing performance of two assays for the measurement of antiâ€Mullerian hormone in premenopausal women: A crossâ€sectional study. Clinical Endocrinology, 2021, 95, 169-175.	2.4	7
308	Human chorionic gonadotrophin-induced suppression of serum inhibin involves reduction in ovarian inhibin α-subunit messenger RNA levels in the pregnant mare serum gonadotrophin-primed female rat. Molecular and Cellular Endocrinology, 1989, 61, 123-128.	3.2	6
309	Hormone-Replacement Therapy Compared with Simvastatin for Postmenopausal Women with Hypercholesterolemia. New England Journal of Medicine, 1998, 338, 63-64.	27.0	6
310	Comparison of effects of pravastatin and hormone therapy on soluble P-selectin and platelet P-selectin expression in postmenopausal hypercholesterolemic women. Maturitas, 2006, 53, 158-165.	2.4	6
311	Androgen Replacement Therapy in Androgen-Deficient Women with Hypopituitarism. Drugs, 2008, 68, 2085-2093.	10.9	6
312	Testosterone in women: can the challenges be met?. Lancet Diabetes and Endocrinology,the, 2015, 3, 588-590.	11,4	6
313	A prospective controlled study of sexual function and sexually related personal distress up to 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy. Menopause, 2021, 28, 748-755.	2.0	6
314	What Are "Normal" Testosterone Levels for Women?. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1842-1843.	3.6	6
315	The use of testosterone after menopause. The Journal of the British Menopause Society, 2004, 10, 65-69.	1.3	5
316	Relationship between the area of cartilage shown on the magnetic resonance imaging middleâ€slice image of the medial and lateral tibial cartilages with cartilage volume and grade of osteoarthritis over time. Scandinavian Journal of Rheumatology, 2004, 33, 87-93.	1.1	5
317	Treatment of vasomotor symptoms in the menopausal transition and postmenopausally: psychiatric comorbidity. Expert Review of Neurotherapeutics, 2007, 7, S115-S137.	2.8	5
318	Androgen use for low sexual desire in midlife women. Menopause, 2013, 20, 795-797.	2.0	5
319	A comparison of the characteristics, treatment and outcome after 5years, of Australian women aged 70+with those aged<70years at the time of diagnosis of breast cancer. Journal of Geriatric Oncology, 2014, 5, 141-147.	1.0	5
320	Authors' reply: Communicating evidence-based practice in menopause. Nature Reviews Disease Primers, $2015, 1, .$	30.5	5
321	Clinical audit of estradiol implant therapy: Long duration of action and implications in non-hysterectomised women. Maturitas, 2016, 94, 84-86.	2.4	5
322	Methodological Challenges in Studying Testosterone Therapies for Hypoactive Sexual Desire Disorder in Women. Journal of Sexual Medicine, 2020, 17, 585-594.	0.6	5
323	Testosterone use in postmenopausal women. Climacteric, 2021, 24, 46-50.	2.4	5
324	Approach to the Patient With New-Onset Secondary Amenorrhea: Is This Primary Ovarian Insufficiency?. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 825-835.	3.6	5

#	Article	IF	CITATIONS
325	Cardiovascular disease prevention in postmenopausal women: a clinician's perspective. Maturitas, 1997, 27, 1-3.	2.4	4
326	Should women be treated with testosterone?. Clinical Endocrinology, 1998, 49, 159-160.	2.4	4
327	The use of androgens for female sexual dysfunction. Nature Reviews Urology, 2006, 3, 176-177.	1.4	4
328	Intended follow up of women with breast cancer at low risk of recurrence and at least 5 years from diagnosis. Internal Medicine Journal, 2014, 44, 332-338.	0.8	4
329	Hormone therapy to treat menopause—breaking a taboo. Nature Reviews Endocrinology, 2014, 10, 6-8.	9.6	4
330	Depressive symptoms and associated factors among Iranian women at midlife: a community-based, cross-sectional study. Menopause, 2019, 26, 1125-1132.	2.0	4
331	International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. Climacteric, 2021, 24, 533-550.	2.4	4
332	An External Perspective on the Report of the International Consensus Development Conference on Female Sexual Dysfunction: More Work to Be Done. Journal of Sex and Marital Therapy, 2001, 27, 131-133.	1.5	3
333	Determining the effects of androgen therapy on sexual well-being: a complex challenge. Menopause, 2005, 12, 359-360.	2.0	3
334	Sexual health consequences of premature ovarian failure. Menopause, 2008, 15, 5-6.	2.0	3
335	Use of imaging in surveillance of women with early stage breast cancer. ANZ Journal of Surgery, 2013, 83, 129-134.	0.7	3
336	Aromatase inhibitors associated with knee subchondral bone expansion without cartilage loss. Climacteric, 2013, 16, 632-638.	2.4	3
337	Menopausal hormone therapy—ovarian cancer risk revisited. Nature Reviews Endocrinology, 2015, 11, 322-323.	9.6	3
338	Vasomotor symptoms are associated with depressive symptoms in community-dwelling older women. Menopause, 2017, 24, 1365-1371.	2.0	3
339	Approach to Managing a Postmenopausal Patient. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 3792-3806.	3.6	3
340	Androgens in premenopausal women and women with premature ovarian insufficiency. Climacteric, 2021, 24, 459-465.	2.4	3
341	The prevalence of hypoactive sexual desire disorder in Australian and Iranian women at midlife. Menopause, 2020, 27, 1274-1280.	2.0	3
342	Identifying and promoting the specific nutrition and physical activity needs of women aged 40 and over. Summary. Medical Journal of Australia, 2000, 173, S109.	1.7	3

#	Article	IF	Citations
343	Acute administration of conjugated equine oestrogen does not improve exercise-induced myocardial ischaemia in men with coronary artery disease. Internal Medicine Journal, 2003, 33, 221-224.	0.8	2
344	Testosterone for low libido in postmenopausal women not using systemic oestrogen therapy. Medical Journal of Australia, 2009, 191, 134-135.	1.7	2
345	A research participant's rights as an ethical dilemma. Australian and New Zealand Journal of Public Health, 2012, 36, 508-510.	1.8	2
346	Routine Screening for Urinary Incontinence in Women: Caution Advised. Annals of Internal Medicine, 2018, 169, 345-346.	3.9	2
347	Menopausal hormone therapy: is there cause for concern?. Lancet Diabetes and Endocrinology,the, 2019, 7, 825-827.	11.4	2
348	Response to Letter to the Editor: "Global Consensus Position Statement on the Use of Testosterone Therapy for Women― Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2313-e2314.	3.6	2
349	Phytoestrogens in the Context of SERMs. , 2002, , 345-363.		2
350	Menopause workplace policy: The way forward or backward?. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2021, 61, 986-989.	1.0	2
351	Letters to the Editor. Menopause, 2003, 10, 102-103.	2.0	2
352	Rationale for Treating Hypoandrogenism in Women. , 2003, , 365-379.		2
353	Functional hypothalamic amenorrhoea: a diagnosis of exclusion. Medical Journal of Australia, 2022, 216, 73-76.	1.7	2
354	Androgens. , 2000, , 445-458.		1
355	Testosterone for Low Libido. New England Journal of Medicine, 2009, 360, 728-729.	27.0	1
356	The Relationship Between Hormone Therapy Use at the Time of Diagnosis of Breast Cancer and Tumor Characteristics. Hormones and Cancer, 2010, 1, 93-99.	4.9	1
357	Climacteric Commentaries. Climacteric, 2011, 14, 505-512.	2.4	1
358	Evaluation of a Bladder Cancer Cluster in a Population of Criminal Investigators with the Bureau of Alcohol, Tobacco, Firearms and Explosivesâ€"Part 1: The Cancer Incidence. Journal of Environmental and Public Health, 2012, 2012, 1-10.	0.9	1
359	Testosterone use in women. , 0, , 494-516.		1
360	Comparison of plain vertebral X-ray and dual-energy X-ray absorptiometry for the identification of older women for fracture prevention in primary care. Internal Medicine Journal, 2013, 43, 38-45.	0.8	1

#	Article	IF	CITATIONS
361	Authors' response to Letter to the Editor on awareness of breast cancer and barriers to breast screening uptake in Bangladesh: A population-based survey. Maturitas, 2016, 88, 58.	2.4	1
362	Is Estrogen the Antidote for Menopausal Depression?. Journal of Women's Health, 2017, 26, 1-2.	3.3	1
363	Identification of the Gender-Specific Health Needs of Women Following Lung Transplantation. Journal of Women's Health, 2018, 27, 485-491.	3.3	1
364	Awareness and use of iodine supplementation among Australian women attending a low-risk pregnancy clinic. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2018, 58, E16-E17.	1.0	1
365	Menopause – a new beginning. Climacteric, 2018, 21, 306-307.	2.4	1
366	Prevalence of and Risk Factors for Depressive Symptoms and Antidepressant Use in Young Australian Women: A Cross-Sectional Study. Journal of Women's Health, 2020, 30, 997-1005.	3.3	1
367	Use of Testosterone in Postmenopausal Women. Endocrinology and Metabolism Clinics of North America, 2021, 50, 113-124.	3.2	1
368	Testosterone and androstenedione are positively associated with antiâ€Müllerian hormone in premenopausal women. Clinical Endocrinology, 2021, 95, 752-759.	2.4	1
369	Preliminary indication of a high prevalence of polycystic ovary syndrome in indigenous Australian women. Gynecological Endocrinology, 2002, 16, 443-446.	1.7	1
370	Androgen Replacement in Women. , 1999, , 401-417.		1
371	Postmenopausal women taking oestrogen plus progestin are at greater risk of ischaemic stroke. Evidence-based Cardiovascular Medicine, 2003, 7, 197-198.	0.0	O
372	Transition to raloxifene with and without low-dose estrogen therapy in postmenopausal women: effects on serum lipids and fibrinogen - a pilot study. Climacteric, 2003, 6, 347-353.	2.4	0
373	Self-reported Sexual Function in Women and Androgen Levels. JAMA - Journal of the American Medical Association, 2005, 294, 2167.	7.4	О
374	Current Perspectives on the Use of Androgens in Women. Seminars in Reproductive Medicine, 2006, 24, 069-070.	1.1	0
375	Testosterone for Low Libido in Postmenopausal Women Not Taking Estrogen: A Phase III Research Study of Female Sexual Dysfunction in Women on Testosterone Patch Without Estrogen (APHRODITE). Obstetrical and Gynecological Survey, 2009, 64, 170-172.	0.4	О
376	Dehydroepiandrosterone Replacement for Postmenopausal Women. Obstetrical and Gynecological Survey, 2011, 66, 490-491.	0.4	0
377	Climacteric commentaries. Climacteric, 2011, 14, 598-606.	2.4	0
378	Climacteric Commentaries. Climacteric, 2012, 15, 398-406.	2.4	0

#	Article	IF	CITATIONS
379	Cosmetic surgery prior to diagnosis of breast cancer. Climacteric, 2012, 15, 195-199.	2.4	o
380	Can the severity of menopausal symptoms be predicted?. BMJ: British Medical Journal, 2012, 344, d7664-d7664.	2.3	0
381	Evaluation of a Bladder Cancer Cluster in a Population of Criminal Investigators with the Bureau of Alcohol, Tobacco, Firearms and Explosives—Part 2: The Association of Cancer Risk and Fire Scene Investigation. Journal of Environmental and Public Health, 2013, 2013, 1-10.	0.9	0
382	Urinary Incontinence in Young Nulligravid Women. Annals of Internal Medicine, 2013, 158, 139.	3.9	0
383	Application Site Affects the Pharmacokinetics of Topical Testosterone Applied to the Axilla Compared With the Inner Arm. Clinical Therapeutics, 2014, 36, 1395-1401.	2.5	0
384	Androgen therapy for postmenopausal women. , 0, , 136-141.		0
385	Reply. Arthritis and Rheumatology, 2015, 67, 315-316.	5.6	0
386	Educating other practitioners on how to assess menopausal women. Maturitas, 2015, 81, 124.	2.4	0
387	The use of micronised progesterone for menopausal hormone therapy, a clinical practice audit. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2016, 56, 323-325.	1.0	0
388	Androgens in postmenopausal women. Gynakologische Endokrinologie, 2018, 16, 123-127.	0.1	0
389	What is the position of testosterone in the care of women?. Climacteric, 2019, 22, 427-428.	2.4	0
390	Iron insufficiency among young Australian women: a populationâ€based survey. Internal Medicine Journal, 2020, 50, 420-426.	0.8	0
391	Reflecting back and looking forward. Climacteric, 2020, 23, 530-531.	2.4	0
392	Response to Letter to the Editor: "Distribution of Body Hair in Young Australian Women and Associations with Serum Androgen Concentrationsâ€, Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3049-e3050.	3.6	0
393	Androgen Therapy for Postmenopausal Women. , 2020, , 187-193.		0
394	Letter to the Editor: "Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline― Journal of Clinical Endocrinology and Metabolism, 2021, 106, e1917-e1918.	3.6	0
395	Phytoestrogens as Hormone Replacement Therapy for Postmenopausal Symptoms. Growth Hormone, 2000, , 83-107.	0.2	0
396	Androgen Deficiency and Abnormality in Women. , 2002, , 477-488.		0

#	Article	IF	CITATIONS
397	Estrogen and Androgen: Mood, Sexual Function, and Quality of Life in the Menopausal Woman. Medical Science Symposia Series, 2002, , 291-301.	0.0	0
398	Transdermal testosterone treatment in women. , 2005, , 67-73.		0
399	Intervention: Androgens., 2007,, 799-812.		0
400	Effect of Testosterone Therapy versus Other Factors on the Self-reported Sexual Satisfaction of Premenopausal Women. Annals of Internal Medicine, 2008, 149, 361.	3.9	0
401	"Add-Back" Estrogen Reverses Cognitive Deficits Induced by a Gonadotropin-Releasing Hormone Agonist in Women with Leiomyomata UteriAuthor's Response. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 702-702.	3.6	0
402	Letter to the Editor: Randolph J, et al. Masturbation Frequency and Sexual Function Domains Are Associated With Serum Reproductive Hormone Levels Across the Menopausal Transition. Journal of Clinical Endocrinology and Metabolism, 2015, 100, L25-L25.	3.6	0
403	SAT-LB001 Traditional Sex Steroids and Ketoandrogen Levels by Menstrual Cycle Stage, Age and Body Mass Index in Women Aged 18-39 Years. Journal of the Endocrine Society, 2019, 3, .	0.2	0
404	Reply: A single cut-off value of anti-Mullerian hormone should not be used for the diagnosis of PCOS in all reproductive-aged women. Human Reproduction, 2022, , .	0.9	0
405	Transition to raloxifene with and without low-dose estrogen therapy in postmenopausal women: effects on serum lipids and fibrinogen - a pilot study. Climacteric, 2003, 6, 347-53.	2.4	0
406	Visceral fat accumulation and cardiovascular disease risk profile. Climacteric, 2011, 14, 599-600.	2.4	0
407	Climacteric commentaries. Sexual activity and satisfaction in community-dwelling older women. Climacteric, 2012, 15, 399-400.	2.4	0
408	Transition to raloxifene with and without low-dose estrogen therapy in postmenopausal women: effects on serum lipids and fibrinogen - a pilot study. Climacteric, 2003, 6, 347-353.	2.4	0
409	Phytoestrogens in the Context of SERMs. , 0, , 345-364.		O